Last edition
News about "Janssen announces positive results from phase 3 GL"
The Janssen Pharmaceutical Companies of Johnson & Johnson announced primary results from the pivotal phase 3 GLOW study (NCT03462719) evaluating fixed-duration Imbruvica plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL)
Janssen Announces Positive Results From Phase 3 GL | 14/06/2021 | By Darshana | 253
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members